Silk Road Medical, Inc (NASDAQ:SILK) Q4 2023 Earnings Call Transcript February 28, 2024 4:30 PM ET

Company Participants

Marissa Bych - IR, Gilmartin Group IR

Chas McKhann - CEO

Lucas Buchanan - CFO and COO

Conference Call Participants

Rick Wise - Stifel

Frank Takkinen - Lake Street Capital Markets

Suraj Khalia - Oppenheimer & Co.

Kristen Stewart - C.L. King

Operator

Good day and thank you for standing by. Welcome to the Silk Road Medical’s 2023 Fourth Quarter Earnings Conference Call. At this time all participants are in listen-only mode. After the speaker's presentation there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Marissa Bych, with Gilmartin Group Investor Relations. Please go ahead.

Marissa Bych

Great. Thank you all for joining today's call. Earlier today, Silk Road Medical released financial results for the three months and the year ended December 31, 2023. A copy of the press release is available on the company's website.

Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including without limitation, those relating to our operating trends and future financial performance, expense management, expectations for hiring and growth in our organization and our business, physician training and adoption, market opportunity and penetration, commercial and international expansion, regulatory approvals, reimbursement, competition, and product development are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the risk factor section of our latest annual report on Form 10-K filed with the Securities and Exchange Commission.

Additionally, Silk Road Medical refers to adjusted EBITDA a non-GAAP financial measure. A reconciliation of adjusted EBITDA to net loss, which is the most directly comparable GAAP measure, is included in our press release, which is available on our website. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, February 28, 2024. Silk Road Medical disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise.